Tokyo – February 26-27, 2026 – The Targeted Therapies Partnering & Licensing Summit Asia is set to unite industry leaders, investors, and biopharma innovators across the region to explore emerging opportunities in targeted oncology and immunology therapies, including ADCs, Bispecific Antibodies, TCEs, TPD/PROTACs, and Radiopharmaceuticals.
As favourable infrastructure and efficiencies draw Western pharma and biotech to fuel clinical pipelines, Asia is now a hotspot for high-value in-licensing and strategic partnerships. Recent industry reports indicate high value ADC and bispecific licensing deals in China, with TCRs and TPD programs also attracting increasing global attention as next-gen drug classes offering enhanced precision and potency.
“Whether tackling ADC resistance, broadening T-cell engager applications, developing new PROTACs or MGDs, or validating radioligand therapies, the energy for collaborations and licensing deals is a promising route for non-dilutive capital, and to secure funds for further clinical development” said Grace Robertson, Co-Founder of the Partnering & Licensing Summits at Hanson Wade. “We are excited about the format of this conference to enable global pharma and local biotech to connect, progress in-person relationships for licensing deals, and ultimately play a part in the clinical progress of next-generation therapies. It’s global exposure and local Asia advantage”
Conference Highlights:
- 100% alignment across research focus, business needs and individual responsibilities to increase the efficiency and results of networking
- Global pharma business development panel discussion to hear pharma’s wants and needs
- Asia investors formal networking session to understand excitement around investing
- Informal drinks and networking reception to connect with other attendees
Why Attend:
- Access high-value assets. Discover de-risked, early clinical programs with significant licensing potential
- Engage with top-tier partners. Connect with decision-makers from innovative biotechs and global pharma
- Gain market intelligence. Understand Asia’s evolving deal-making landscape, including geographic carve-outs, milestone structures, and strategic collaborations
The event will take place from February 26-27, 2026 at The Westin Tokyo. Registration is open at https://ter.li/ggwa66.
About Targeted Partnering & Licensing Asia:
Following successful iterations in US, the Targeted Therapies Partnering & Licensing Summit Asia is built so that global multi-national (MNC) pharma can connect with biotech business development and discuss new licensing and co-development opportunities.
Media Contact:
Hanson Wade
info@hansonwade.com
US: +1 617 455 4188
UK: +44 (0)20 3141 8700